GT Biopharma, Inc.

Management did not report quarterly revenue or EPS on this call. The key disclosed hard numbers were that 12 patients had been treated in the GTB-3550 Phase I study; four patients showed reported CD33-positive bone marrow blast reductions of 33%, 61%, 63%, and 50%; 57% of patients treated between 25 and 150 micrograms experienced a reduction in AML or MDS blasts; and one Grade 1 CRS case was reported at the 150 microgram dose, with no other clinically significant toxicities. The company said it had approximately $40 million in cash and expects that to fund its business plans for the next couple of years. Management said ESMO in September would include updated safety data through at least 12 patients, that the 200 microgram cohort would be dosed next week, and that final Phase I data would likely come later in the fall, with a conference presentation later in the winter or early spring or possibly a press release before then.

Tony Cataldo framed the quarter as a milestone period, citing the Russell 2000 and Chicago Options Exchange additions, the new sponsored research agreement with the University of Minnesota, and the company’s cash position. His tone was upbeat and emphatic about the TriKE platform, repeatedly stressing that the data rather than management would validate the story. He also signaled a strategy of proving monotherapy first, then moving quickly into combination studies, especially in AML and potentially in solid tumors.

There was no traditional CFO prepared commentary or detailed balance sheet discussion on the call. The most finance-related point came from management’s statement that GT Biopharma had about $40 million, which they said should cover execution of business plans for the next couple of years. They also noted they were bringing on multiple new sites for Phase II and expected up to 8 to 10 total sites, which implies spending and development scale-up rather than near-term profitability commentary.

Analysts focused on the timing and content of ESMO and final GTB-3550 data, the significance of the Grade 1 CRS event, Dr. Jeffrey Miller’s ongoing role, the treatment setting for AML, the B7H3 program, combination strategy, and whether the Wisconsin site would open. Management said ESMO would show updated safety data through at least 12 patients, with patient 13 dosing next week, and that final Phase I data was still a few months away because the MTD had not yet been established. They described the CRS event as fever only, not dose limiting, said Dr. Miller would remain actively involved, and explained that Wisconsin and Oregon sites were ready but held for Phase II, while they also plan to pursue combinations such as venetoclax plus TriKE and dual-targeting designs to reduce immune escape.